Article

Journal of Cardiovascular Translational Research

, Volume 7, Issue 1, pp 91-100

First online:

Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial

  • Stefanie SchulzAffiliated withDeutsches Herzzentrum München, Technische Universität MünchenISAResearch Center, Deutsches Herzzentrum München Email author 
  • , Dominick J. AngiolilloAffiliated withUniversity of Florida College of Medicine
  • , David AntoniucciAffiliated withCareggi Hospital Firenze
  • , Isabell BernlochnerAffiliated with1. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München
  • , Christian HammAffiliated withKerckhoff KlinikDZHK, Partner Site Rhine-Main
  • , Juliane JaitnerAffiliated with1. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München
  • , Karl-Ludwig LaugwitzAffiliated with1. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität MünchenDZHK, Partner Site Munich Heart Alliance
  • , Katharina MayerAffiliated withDeutsches Herzzentrum München, Technische Universität München
  • , Barbara von MerzljakAffiliated withDeutsches Herzzentrum München, Technische Universität München
    • , Tanja MorathAffiliated withDeutsches Herzzentrum München, Technische Universität München
    • , Franz-Josef NeumannAffiliated withHerzzentrum Bad Krozingen
    • , Gert RichardtAffiliated withHerzzentrum der Segeberger Kliniken
    • , Judith RufAffiliated withDeutsches Herzzentrum München, Technische Universität München
    • , Gisela SchömigAffiliated withDeutsches Herzzentrum München, Technische Universität München
    • , Helmut SchühlenAffiliated withVivantes, Auguste-Viktoria-Klinikum
    • , Heribert SchunkertAffiliated withDeutsches Herzzentrum München, Technische Universität MünchenDZHK, Partner Site Munich Heart Alliance
    • , Adnan KastratiAffiliated withDeutsches Herzzentrum München, Technische Universität MünchenDZHK, Partner Site Munich Heart Alliance
    • , Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial Investigators

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

In acute coronary syndromes (ACS), a dual antiplatelet regimen with an adenosine diphosphate (ADP) receptor antagonist plus aspirin has become the cornerstone of treatment. The third-generation thienopyridine prasugrel and the cyclopentyl-triazolo-pyrimidine ticagrelor provide a greater, more rapid and consistent platelet inhibition compared to their predecessor clopidogrel. Based on their advantages over clopidogrel in two landmark studies, both drugs received a class I recommendation for their use in ACS patients with and without ST segment elevation. Due to differences in ACS populations and conditions investigated, the relative merits of ticagrelor versus prasugrel in the treatment of ACS patients with planned invasive strategy cannot be reliably estimated from independent trials. To date, no direct head-to-head comparison of ticagrelor and prasugrel in terms of clinical outcome exists. The aim of this multicenter, randomized, open-label trial is to assess whether ticagrelor is superior to prasugrel in ACS patients with planned invasive strategy.

Keywords

Ticagrelor Prasugrel Acute coronary syndrome PCI